EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

SSGJ ‐613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double‐Blind, Phase II Study

Yu Xue, Xiaoxia Zhu, Baoyu Zhang, Yanlin Li iD, Wei Gou, Lie Dai, Ning Zhang, Lin Tang, Zhenchun Zhang, Lingli Dong, Xiaobing Yang, Jian Xu und 5 weitere

International Journal of Rheumatic Diseases · 2026

DOI: 10.1111/1756-185x.70798 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Yu Xue und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthralgia, Arthritis, Gouty, Gout Suppressants. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This phase II trial aimed to evaluate the efficacy and safety of SSGJ‐613, a fully human anti‐interleukin 1β monoclonal antibody, compared with compound betamethasone (CB) in Chinese patients with acute gouty arthritis.

Methods

In this multicenter, double‐blind, double‐dummy, active‐controlled study, 90 adults with gout according to the 2015 American College of Rheumatology (ACR) criteria and who had experienced an acute gouty arthritis flare within 7 days were randomized (1:1:1) to receive a single subcutaneous injection of SSGJ‐613 (200 mg or 300 mg) or intramuscular CB. The primary endpoint was the change from baseline in visual analog scale (VAS) pain scores at 72 h post‐dosing. Safety was evaluated through monitoring of adverse events and laboratory parameters.

Results

The mean changes from baseline in VAS scores at 72 h were comparable between SSGJ‐613200 mg (−45.8 mm), 300 mg (−40.4 mm), and CB (−48.2 mm) groups. However, SSGJ‐613 significantly reduced the risk of new flares: 16.7% (200 mg) and 14.3% (300 mg) of patients experienced new flares versus 54.8% with CB ( p = 0.0037 and p = 0.0019, respectively). The safety profile of SSGJ‐613 was similar to CB, with no drug‐related serious adverse events reported.

Conclusion

A single injection of SSGJ‐613 demonstrated rapid pain relief comparable to corticosteroid therapy at 72 h and provided superior protection against gout flare recurrence over 12 weeks in Chinese patients, supporting its potential as an effective treatment option for acute gouty arthritis with prolonged therapeutic benefits. Clinical Trials NCT06169891.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthralgiaArthritis, GoutyGout SuppressantsInterleukin-1betaAdultAgedFemaleHumansMaleMiddle AgedBetamethasoneChinaDouble-Blind MethodInjections, IntramuscularInjections, SubcutaneousPain MeasurementSymptom Flare UpTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Acute gouty arthritisGoutInterleukin‐1β (IL‐1β) inhibitionSSGJ‐613

Substanzen

Antibodies, Monoclonal, HumanizedBetamethasoneGout SuppressantsIL1B protein, humanInterleukin-1beta

Autor:innen und Institutionen

  • Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Endocrinology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Department of Nephrology, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China.
  • Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China.
  • Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Yanlin Li, Zhijun Li, Jing Yang, Hejian Zou

Förderung

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Zitieren

APA

Xue, Y., Zhu, X., Zhang, B., Li, Y., Gou, W., Dai, L., Zhang, N., Tang, L., Zhang, Z., Dong, L., Yang, X., Xu, J., Li, Z., Yang, J., Lou, J., Liu, Y., & Zou, H. (2026). SSGJ ‐613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double‐Blind, Phase II Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70798

Vancouver

Xue Y, Zhu X, Zhang B, Li Y, Gou W, Dai L, et al. SSGJ ‐613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double‐Blind, Phase II Study. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70798

BibTeX
@article{Xue2026,
  author = {Xue, Yu and Zhu, Xiaoxia and Zhang, Baoyu and Li, Yanlin and Gou, Wei and Dai, Lie and Zhang, Ning and Tang, Lin and Zhang, Zhenchun and Dong, Lingli and Yang, Xiaobing and Xu, Jian and Li, Zhijun and Yang, Jing and Lou, Jing and Liu, Yanli and Zou, Hejian},
  title = {SSGJ ‐613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double‐Blind, Phase II Study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  doi = {10.1111/1756-185x.70798}
}
Kostenlos starten →